Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03556228 · ClinicalTrials.gov registry record · Phase 1
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
A Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by VM Oncology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 242
- Enrollment target
- 15
- Study locations
NCT03556228: Recruiting Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by VM Oncology.
NCT03556228 is a Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer that is actively recruiting participants, run by VM Oncology. The registered enrollment target is 242 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (63% lower). The trial reports 15 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03556228, a Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, is actively recruiting participants, sponsored by VM Oncology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 242 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists
Primary Outcome
TEAE
Conditions Studied
Interventions
- DRUG VMD-928 100 mg Tablet
- DRUG VMD-928 Tablet and Pembrolizumab (200 mg)
Study Locations (15)
New Jersey
- Englewood Hospital and Medical Center (site 202) - Englewood
- Summit Medical Group (site 205) - Florham Park
- Atlantic Health System, Morristown Medical Center (site 124) - Morristown
Florida
- Holy Cross Hospital (site 213) - Fort Lauderdale
- Memorial Cancer Institute at Memorial Healthcare Systems (site 132) - Pembroke Pines
California
- Providence Medical Foundation (site 209) - Santa Rosa
Connecticut
- Hartford Hospital (site 210) - Hartford
District of Columbia
- The George Washington University Cancer Center (site 212) - Washington D.C.
New Mexico
- Presbyterian Kaseman Hospital (site 208) - Albuquerque
New York
- Weill Cornell Medicine, Cornell University (site 126) - New York
Ohio
- Taylor Cancer Research Center (site 204) - Maumee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2018-06-08 |
| Est. Completion | 2028-06 |
| Phase | Phase 1 |
What NCT03556228 shows while recruiting
NCT03556228 is an interventional study that assigns participants to a tested intervention. The registered 242 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (63% lower).
The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which VMD-928 100 mg Tablet is the first listed.
NCT03556228 lists 15 locations in 12 states (New Jersey, Florida, California).
Frequently Asked Questions
What is clinical trial NCT03556228 about?
NCT03556228 is a clinical study titled "VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma". This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curati...
What is the current status of trial NCT03556228?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 242 participants. The study started on 2018-06-08. Estimated completion is 2028-06.
What conditions does trial NCT03556228 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Lung Cancer, Pancreatic Cancer, Esophageal Cancer, Head and Neck Squamous Cell Carcinoma.
What interventions are being tested in trial NCT03556228?
The interventions under investigation include: VMD-928 100 mg Tablet (DRUG), VMD-928 Tablet and Pembrolizumab (200 mg) (DRUG).
Who is sponsoring clinical trial NCT03556228?
This trial is sponsored by VM Oncology, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03556228 being conducted?
This trial has 15 study locations across California, Connecticut, District of Columbia, Florida, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03556228's enrollment target sits among peer trials
242 153rd of 454 higher than 302 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04260022 · 242 participants · Phase 1
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- NCT04459000 · 242 participants · NA
Substance Use Treatment and Access to Resources (STARS) Project
- NCT05644496 · 242 participants · Phase 4
ZYNRELEF for Pain Management in Total Knee Arthroplasty
- NCT05783765 · 242 participants · NA
Food Genetics Behavior Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI